The largest database of trusted experimental protocols
> Chemicals & Drugs > Pharmacologic Substance > Selective Estrogen Receptor Modulators

Selective Estrogen Receptor Modulators

Selective Estrogen Receptor Modulators (SERMs) are a class of compounds that interact with estrogen receptors and can exhibit either estrogen agonist or antagonist effects, depending on the specific tissue and receptor subtype.
These agents are used in the treatment of estrogen-responsive cancers, as well as for the prevention and treatment of osteoporosis.
SERMs can also have effects on cardiovascular and central nervous system function.
PubCompare.ai's AI-driven platform can optimize your SERM research by helping you locate the best protocols from literature, pre-prints, and patents, enhancing reproducibility and accuracy.
Leverage AI-powered comparisons to identify the most effective SERM products and procedures.

Most cited protocols related to «Selective Estrogen Receptor Modulators»

Sexual differentiation was induced in tightly synchronized P. falciparum parasites (28±2 hpi) by incubating the cells for 22 hours in CM (220 μL per well of a 96-well plate; 0.3-0.5% parasitemia; 2.5% hematocrit) or in −SerM as described (Brancucci et al., 2015 (link)). If not stated otherwise, cell line Pf2004/164tdTom was used for all experiments. To determine the effect of culture perturbations on sexual commitment, serum fractions as well as nutrients or inhibitor compounds (solved in either RPMI, DMSO, chloroform, ethanol or methanol) were added to the bottom of empty wells (glass bottom dishes were used for chloroform-containing samples) and directly resuspended in parasite culture after allowing volatile solvents to evaporate. To determine sexual differentiation in reticulocyte-enriched blood, tightly synchronized parasites were magnet purified at 46±2 hpi using MACS CS columns in a SuperMACS (Miltenyi Biotec) before incubating pure schizont-infected erythrocytes (>99%) with the blood sample to be tested. These culture perturbations were then tested for effects on parasite sexual differentiation as described (Brancucci et al., 2015 (link)). In brief, following the 22 hour testing phase (see above), cells of each well were washed 3 times in 200 μL +SerM medium before being resuspended in 220 μL +SerM medium. Henceforth, medium was exchanged daily. Parasitemia and gametocytemia was quantified using flow cytometry at 20-30 hpi (MACS Quant, Analyzer 10) and 72-96 hpi (BD Fortessa), respectively. Cytometry data were analysed using FlowJo software and sexual differentiation rates were determined by dividing gametocytemia of each well with the corresponding parasitemia measurements. Assays were run in biological triplicates. Each biological replicate contained technical triplicates.
P. berghei sexual commitment assays were performed using a parasite line expressing an RFP reporter under the gametocyte-specific gene PBANKA_1018700 (Sinha et al., 2014 (link)) and GFP under the constitutive PBANKA_0905600 promoter, in the 507cl1 background line (RMgm-7). Mature schizonts were intravenously (IV) administered to naïve TO mice. Ring stage parasites were isolated at 4 hpi and mature trophozoites and gametocytes were removed by passing through a MACS LD column (Miltenyi Biotec). Infected erythrocytes were incubated in −SerM medium, −SerM medium supplemented with 20 μM LysoPC (−SerM/LysoPC), or serum-complemented medium (+SerM) for 20 hours. Mature schizont stage parasites were then isolated on a 55% Nycodenz (Axis-Shield POC)/RPMI gradient and injected intravenously into 2 or 3 naïve mice. GFP-expressing cells were examined by flow cytometry at 16 hpi to calculate parasitemia, while cells expressing both RFP and GFP (gametocytes) were assessed at 21 hpi. Gametocytemia was calculated as [(RFP+ and GFP+ cells)/GFP+ cells]100.
Full text: Click here
Publication 2017
Biological Assay Biopharmaceuticals BLOOD Cell Lines Cells Chloroform DNA Replication Epistropheus Erythrocytes Ethanol Flow Cytometry Genes, Reporter Hyperostosis, Diffuse Idiopathic Skeletal LY353381hydrochloride LYSO-PC Methanol Mus Nutrients Nycodenz Parasitemia Parasites Reticulocytes Schizonts Selective Estrogen Receptor Modulators Serum Sex Differentiation Solvents Sulfoxide, Dimethyl Trophozoite Volumes, Packed Erythrocyte
The trial was conducted at 4 MsFlash network sites (Appendix 1). Participants were recruited from July 2009 to June 2010, primarily by mass mailing to age-eligible women on purchased mailing lists or health-plan enrollment files. Eligible women were ages 40–62 years, in the menopause transition (amenorrhea >=60 days in the past year), or postmenopausal (>=12 months since last menstrual period or bi-lateral oophorectomy), or had a hysterectomy with one or both ovaries remaining and FSH >20 mIU/mL and estradiol <=50 pg/mL; and were in general good health as determined by medical history, a brief physical exam and standard blood tests.
The required hot flash criteria were >=4 hot flashes or night sweats per day (24 hours) (an average of >=28 hot flashes/night sweats per week) recorded on daily hot flash diaries for 3 weeks in the screening period. Hot flashes/ night sweats had to be rated as bothersome (moderate or a lot) or severe (moderate or severe) on 4 or more days per week.
Exclusion criteria included use of psychotropic medications, prescription, over-the-counter, or herbal therapies for hot flashes in the past 30 days; hormone therapy, hormonal contraceptives, selective estrogen receptor modulators (SERMs) or aromatase inhibitors in the past 2 months; current severe medical illness, major depressive episode, drug or alcohol abuse in the past year; suicide attempt in the past 3 years; lifetime diagnosis of bipolar disorder or psychosis, uncontrolled hypertension, history of endometrial or ovarian cancer, myocardial infarction, angina or cerebrovascular events or lack of non-hormonal contraception if sexually active and not postmenopausal.
Publication 2011
Abuse, Alcohol Angina Pectoris Aromatase Inhibitors Bipolar Disorder Contraceptive Agents Diagnosis Drugs, Non-Prescription Endometrium Estradiol Health Planning Hematologic Tests High Blood Pressures Hormonal Contraception Hormones Hot Flashes Hysterectomy Menopause Menstruation Myocardial Infarction Ovarian Cancer Ovariectomy Ovary Pharmaceutical Preparations Physical Examination Phytotherapy Psychotic Disorders Psychotropic Drugs Selective Estrogen Receptor Modulators Suicide Attempt Sweat Therapeutics Woman
The aim of the China Osteoporosis Prevalence Study was to describe the prevalence of osteoporosis based on BMD, vertebral fracture, and clinical fracture (defined as fracture events recalled by participants on a questionnaire) in the past 5 years among men and women in 5 age groups (40-49 years, 50-59 years, 60-69 years, 70-79 years, and ≥80 years) and in urban and rural areas. We calculated sample weights by sampling clusters and poststratification weights based on the 2010 National Census of China,7 and we calculated the final weights as sample weights multiplied by poststratification weights to represent the general population in China.
We established a mean BMD and SD database for men and women and plotted lumbar spine, femoral neck, and total hip BMD by age and sex using Svysmooth, a smoothing procedure available in the survey package of R, version 4.0.0 (R Project for Statistical Computing).8 We diagnosed osteoporosis based on the peak BMD (SD) in young men and women aged 20 to 39 years that was established in the present study. We used the diagnostic criteria of the World Health Organization: T scores = (BMD − peak BMD of individuals of the same sex)/(SD of peak BMD of individuals of the same sex).9 (link) We defined individuals with T scores of −2.5 or less in any sites (L1 to L4, femoral neck, or total hip) as having osteoporosis. We calculated the weighted prevalence of osteoporosis by sex, age group, and urban vs rural setting. We calculated weighted prevalence of vertebral fracture (based on radiographic findings as described above) and clinical fracture in the past 5 years (based on a questionnaire) by sex, age group, and urban vs rural settings. We calculated the treatment rate among patients with T scores of −2.5 or less in any sites or with a history of fracture (vertebral fracture of grade 2 or higher based on radiographic findings or clinical fracture in the past 5 years based on a questionnaire) and current use of antiosteoporosis treatment (including bisphosphonate, calcitonin, estrogen, parathyroid hormone analogue, selective estrogen receptor modulator, or an active form of vitamin D or its analogue).
We performed multivariable linear regression to investigate factors associated with BMD in the lumbar spine, femoral neck, and total hip. We performed multivariable logistic regression to investigate factors associated with vertebral fracture of grade 2 or higher and clinical fracture in the past 5 years. We used data from all participants for whom the variables of interest were available for analysis and did not impute missing data. We adjusted all P values for multiple testing, present 95% CIs, and considered a 2-sided P < .05 as statistically significant. We performed all data analysis using SAS, version 9.3 (SAS Institute Inc).
Full text: Click here
Publication 2021
Age Groups Calcitonin Diagnosis Diphosphonates Ergocalciferol Estrogens Fracture, Bone Neck, Femur Osteoporosis Parathyroid Hormone Patients Selective Estrogen Receptor Modulators Spinal Fractures Vertebrae, Lumbar Woman X-Rays, Diagnostic
In the Women’s Health Initiative study protocol, participants were required to permanently stop their assigned hormone therapy if they developed the following events: deep vein thrombosis, pulmonary embolus, endometrial hyperplasia with atypia, malignant melanoma, endometrial cancer, breast cancer, triglycerides above 1,000 mg/dL, or starting anticoagulant medications, estrogen, progesterone, testosterone, tamoxifen, or other selective estrogen-receptor modulators. We performed a secondary analysis to estimate the survival curve that would have been observed if all women in the hormone therapy arm had fully complied with this protocol. More specifically, we estimated survival under the dynamic regime “take hormone therapy until one of the above events occurs, then stop taking hormone therapy.” To do so, we artificially censored participants in the hormone arm at the time they deviated from the protocol (i.e., did not stop taking their assigned study hormone after they had one of these events). This artificial censoring may result in selection bias because the distribution of risk factors of breast cancer may differ between the censored and the uncensored.
To adjust for such potential selection bias, one would estimate time-varying, subject-specific inverse probability weights whose denominator is the subject’s estimated probability of remaining uncensored at each time, conditional on past joint predictors of censoring and the outcome. Note, however, that the predictors of censoring at time t are in fact the predictors of hormone therapy continuation at t because those who continue to take their study pills are precisely those who are censored. Therefore there is no need to estimate separate inverse probability weights to adjust for selection bias due to artificial censoring because the treatment weights estimated in the primary analysis already adjust for the potential time-varying selection bias due to artificial censoring. Also note that most protocol-mandated reasons for stopping treatment were not risk factors for breast cancer and thus need not be used to estimate the weights.
The specification of a marginal structural model for dynamic regimes is straightforward when only two regimes are compared23 (link) or when the goal of the structural model is to smooth over a set of regimes that can be placed in 1-to-1 correspondence with an indexing continuous variable.8 ,24 (link) The situation is not so straightforward when, as is required in this example, the dose-response function depends on a summary dose measure (such as cumulative use) that can take the same value for many different regimes. See Appendix 2 for further discussion and caveats. For simplicity, we used the same specification as in the primary analysis; specifically we assumed the log discrete hazard is a linear function of cumulative dose.
Publication 2010
Anticoagulants Atypical Endometrial Hyperplasia Contraceptives, Oral Deep Vein Thrombosis Endometrial Carcinoma Estrogens Hormones Joints Malignant Neoplasm of Breast Melanoma Progesterone Pulmonary Embolism Selective Estrogen Receptor Modulators Tamoxifen Testosterone Treatment Protocols Triglycerides Woman
T47D:A18/PKCα, T47D:A18/neo andT47D:A18-TAM1 tumors were established as previously described (7 (link)). E2 was administered via silastic capsules (1.0 cm) implanted subcutaneously between the scapulae, producing a mean serum E2 level of 379.5 pg/mL (11 (link), 15 (link)). BTC and TTC-352 were administered p.o. at a dose of 1.5 mg/animal daily for 2 weeks as previously described for other SERMs (7 (link)). RAL was administered p.o. at a dose 1.5 mg/animal daily for 2 weeks. Tumor cross-sectional area was determined weekly using Vernier calipers and calculated using the formula: length/2 × width/2 × π. Mean tumor area was plotted against time in weeks to monitor tumor growth. The mice were sacrificed by CO2 inhalation and cervical dislocation, and tumors and uteri were excised, cleaned of connective tissue, and immediately weighed. The Animal Care and Use Committee of the University of Illinois at Chicago approved all of the procedures involving animals.
Publication 2014
Animals Capsule Connective Tissue Inhalation Joint Dislocations Mus Neck Neoplasms PRKCA protein, human Scapula Selective Estrogen Receptor Modulators Serum Silastic Uterus

Most recents protocols related to «Selective Estrogen Receptor Modulators»

This study was a national population-based survey of women with stages I–III breast cancer prescribed ET in Ireland. Eligible women were identified from the records of the population-based National Cancer Registry Ireland and were: (i) aged ≥ 18 years; (ii) had a diagnosis of stages I–III, estrogen (ER) or progesterone (PR) receptor positive breast cancer during 01/07/2009-–30/06/2014; (iii) received tumour-directed surgery; (iv) were prescribed adjuvant ET (selective estrogen receptor modulator, SERM; aromatase inhibitor, AI) within 1 year of breast cancer diagnosis and up to 5 years and were (v) alive. Women were excluded if they had previously been diagnosed with another invasive cancer other than non-melanoma skin cancer (N = 2890 eligible women). GPs (N = 656) screened women for any medical reasons that they should not be invited to take part in the study (e.g. cancer recurrence, metastatic disease, palliative care, deceased) and 355 (12%) were considered to be ineligible. In total, 2535 eligible women were invited, by post, to self-complete a questionnaire measuring; (i) socio-demographics; (ii) modifiable determinants of ET non-adherence and; (iii) non-adherence (Fig. 1). Ethical approval was granted by the Irish College of General Practitioners. Informed consent was obtained from all individual participants included in the study.

Number of participants at each stage of the study

Full text: Click here
Publication 2023
Aromatase Inhibitors Breast Carcinoma Estrogens Familial Atypical Mole-Malignant Melanoma Syndrome General Practitioners Malignant Neoplasm of Breast Malignant Neoplasms Neoplasm Metastasis Neoplasms Operative Surgical Procedures Palliative Care Pharmaceutical Adjuvants Receptors, Progesterone Recurrence Selective Estrogen Receptor Modulators Woman
This study included 82 postmenopausal Mexican mestizo women with primary osteoporosis. Patient recruitment was from January 2017 to July 2019. These patients were referred by an osteoporosis clinic at a civic hospital (Antiguo Hospital Fray Antonio Alcalde) in Guadalajara, Mexico. The inclusion criteria for participants were as follows: (1) had a diagnosis of osteoporosis according to the clinical practice guidelines for the diagnosis and management of osteoporosis [20 (link)]; (2) aged 50 years or older; (3) included in the cohort at the time when they received alendronate (70 mg administered orally once per week) for one year (according to the clinical guidelines for pharmacological treatment of the National Osteoporosis Foundation, USA); (4) received calcium and vitamin D supplementation therapy; (5) had a clinical chart available at the hospital. The exclusion criteria were patients receiving parathyroid hormone therapy, selective estrogen receptor modulators (SERMs), glucocorticoids or biologic therapy, or presenting a secondary comorbidity associated with low BMD (such as thyroid disease or chronic renal failure) or the presence of alcoholism. Only one patient with osteoporosis per family was allowed.
Study development: All the subjects underwent a physical examination and completed a detailed questionnaire on family and medical histories, as well as on lifestyle habits. Body mass index (BMI) was calculated as weight (kg) divided by height squared (m2). Treatment adherence was determined using the questionnaire validation of the Adherence Evaluation of Osteoporosis (ADEOS) treatment for osteoporotic postmenopausal women [21 (link)]. All patients included in the study showed adequate adherence to the treatment.
Full text: Click here
Publication 2023
Alcoholic Intoxication, Chronic Alendronate Calcium Diagnosis Glucocorticoids Index, Body Mass Kidney Failure, Chronic Osteoporosis Osteoporosis, Postmenopausal Parathyroid Hormone Patients Pharmacotherapy Physical Examination Selective Estrogen Receptor Modulators Therapeutics Therapies, Biological Thyroid Diseases Vitamin D Woman
All morbid states during observation as well as at baseline were properly treated over the follow-up period after obtaining informed consent from the participants. All subjects with osteoporosis were asked for receiving osteoporotic treatment. When the patients agreed with treatment, the patients themselves selected the modes of treatment with the advice from clinicians. Definition of the treatment was as follows. The mode of treatment included teriparatide, estrogen, selective estrogen receptor modulators (SERMs), bisphosphonates, or denosumab. When the treatment term exceeded half of the observation period, we defined those subjects as the patients with treatment. Vitamin D analogue, vitamin K2, calcium formulation, or calcitonin were not included in the treatment because of the lack of robust data for preventing fractures. Randomization of the treatment mode was impossible, because the treatment procedure depended upon the patient’s will. The treatment of osteoporosis was basically not changed until the occurrence of incident fracture or adverse event. Thus, the duration of treatment was the same as observation period in nearly all cases.
Full text: Click here
Publication 2023
Calcitonin Calcium Denosumab Diphosphonates Estrogens Fracture, Bone Osteoporosis Patients Selective Estrogen Receptor Modulators Teriparatide Vitamin D Vitamin K2
This single-center prospective study was conducted from January 2019 to December 2020 and followed up on the clinical results of micro-TESE in male patients with idiopathic NOA who were seen in our Center for Reproductive Medicine’s outpatient clinic. We gathered and counted clinical information on age, testicular volume, and reproductive hormones as well as the clinical outcomes of sperm discovered by micro-TESE. Semen will be taken once more on the day of the micro-TESE retrieval to confirm azoospermia in all patients who performed at least three preoperative centrifugal semen tests that demonstrated azoospermia. Idiopathic NOA was defined after comprehensive diagnostic evaluations of all know causes for non-obstructive azoospermia. Patients who met the following criteria were excluded: (1) chromosomal disorders previously linked to azoospermia, such as AZFa/b/c microdeletions on the Y chromosome, Klinefelter syndrome, or Kallman syndromes; mutations of the cystic fibrosis conductance regulator gene linked to congenital bilateral absence of the vas deferens; (2) hypothalamic/pituitary defects; (3) testicular tumors; (4) testicular factors (cryptorchidism, varicocele, and disturbances of erection/ejaculation) linked to infertility; (5) using drugs that alter hormone levels (e.g., exogenous testosterone, selective estrogen receptor modulators, gonadotropins, or aromatase inhibitors); (6) either testicular or pituitary surgery, or a previous vasectomy.
Full text: Click here
Publication 2023
Aromatase Inhibitors Azoospermia Azoospermia, Nonobstructive Congenital bilateral aplasia of vas deferens Cryptorchidism Cystic Fibrosis Diagnosis Disorder, Chromosomal Ejaculation Genes, Regulator Gonadotropins Hormones Hypothalamus Kallmann Syndrome Klinefelter Syndrome Males Mutation Operative Surgical Procedures Patients Penile Erection Pharmaceutical Preparations Reproduction Selective Estrogen Receptor Modulators Semen Sperm Sterility, Reproductive Testicular Neoplasms Testosterone Varicocele Vasectomy Vision Y chromosome deletions

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2023
Atypical Endometrial Hyperplasia Biopsy Carcinoma Curettage Diabetes Mellitus Diagnosis Endometrial Carcinoma Endometrium Ethics Committees, Research Fertility Hereditary Nonpolyposis Colorectal Cancer High Blood Pressures Hyperplasia Hysterectomy Malignant Neoplasm of Breast Menopause Neoplasms Obesity Pathological Dilatation Patients Precancerous Conditions Selective Estrogen Receptor Modulators Therapy, Hormone Replacement Ultrasonics Woman

Top products related to «Selective Estrogen Receptor Modulators»

Sourced in United States, Germany, United Kingdom, China, Italy, Sao Tome and Principe, France, Macao, India, Canada, Switzerland, Japan, Australia, Spain, Poland, Belgium, Brazil, Czechia, Portugal, Austria, Denmark, Israel, Sweden, Ireland, Hungary, Mexico, Netherlands, Singapore, Indonesia, Slovakia, Cameroon, Norway, Thailand, Chile, Finland, Malaysia, Latvia, New Zealand, Hong Kong, Pakistan, Uruguay, Bangladesh
DMSO is a versatile organic solvent commonly used in laboratory settings. It has a high boiling point, low viscosity, and the ability to dissolve a wide range of polar and non-polar compounds. DMSO's core function is as a solvent, allowing for the effective dissolution and handling of various chemical substances during research and experimentation.
Sourced in United States, Germany, United Kingdom, Japan, Sao Tome and Principe, China, France, Macao, Switzerland, Israel, Belgium, Hungary, Canada, Italy
17β-estradiol is a natural estrogen hormone produced by the ovaries, adrenal glands, and other tissues in the body. It is a key component in various laboratory and research applications, serving as a substrate, reference standard, or analytical tool for the study of estrogen-related processes and pathways.
Sourced in United States, United Kingdom
SYPRO Orange dye is a fluorescent dye used for the detection and quantification of proteins in various applications, such as SDS-PAGE and Western blotting. It binds to the hydrophobic regions of proteins, emitting an orange fluorescence upon excitation, allowing for sensitive and accurate protein visualization.
Sourced in United Kingdom, United States
DAMGO is a synthetic opioid peptide that acts as a selective agonist for the mu-opioid receptor. It is commonly used in research applications to study the pharmacology and function of the mu-opioid receptor.
Sourced in United States, Germany
Raloxifene is a selective estrogen receptor modulator (SERM) used as a laboratory reagent. It functions by selectively binding to and modulating the activity of estrogen receptors in target tissues.
Sourced in United Kingdom, United States
The Mx3005P qPCR System is a real-time PCR instrument designed for quantitative gene expression analysis. It provides precise temperature control and detection capabilities for accurate and reliable quantification of DNA and RNA samples.
Sourced in United Kingdom, United States
WIN55,212-2 is a synthetic cannabinoid receptor agonist. It binds to and activates both CB1 and CB2 cannabinoid receptors. This product is intended for laboratory research use only.
Sourced in United States
[35S]GTPγS is a radiolabeled GTP analog used in biochemical assays to study guanine nucleotide binding proteins and their interactions.
Sourced in United States
The Cytation 5 is an automated multi-mode microplate reader designed for cell imaging and detection applications. It combines high-performance microplate detection and cellular analysis capabilities in a single, configurable instrument.
Sourced in United States, Germany
Total STAT3 is a lab equipment product that measures the total amount of STAT3 protein in a sample. STAT3 is a transcription factor that plays a critical role in cellular processes such as cell growth and survival. The Total STAT3 product provides a quantitative assessment of the total STAT3 protein level in a given sample.

More about "Selective Estrogen Receptor Modulators"

Selective Estrogen Receptor Modulators (SERMs) are a class of compounds that interact with estrogen receptors, exhibiting either estrogen agonist or antagonist effects depending on the specific tissue and receptor subtype.
These agents are used in the treatment of estrogen-responsive cancers, as well as for the prevention and treatment of osteoporosis.
SERMs can also have effects on cardiovascular and central nervous system function.
PubCompare.ai's AI-driven platform can optimize your SERM research by helping you locate the best protocols from literature, pre-prints, and patents, enhancing reproducibility and accuracy.
Leverage AI-powered comparisons to identify the most effective SERM products and procedures.
Explore the diverse applications of SERMs, from their use in managing estrogen-dependent cancers like breast cancer to their role in maintaining bone health and preventing osteoporosis.
Delve into the mechanistic insights of how these selective modulators interact with estrogen receptors, exhibiting both agonistic and antagonistic effects in a tissue-specific manner.
Beyond their primary therapeutic applications, SERMs have been shown to influence cardiovascular and neurological functions, underscoring their multifaceted impact on the human body.
Discover how PubCompare.ai's cutting-edge AI technology can streamline your SERM research, empowering you to uncover the most effective protocols and products.
Whether you're investigating the use of SERMs in oncology, osteoporosis management, or exploring their broader physiological effects, PubCompare.ai's platform can be your invaluable ally, enhancing the reproducibility and accuracy of your research endeavors.
Leverage the power of AI to navigate the vast landscape of SERM-related literature, pre-prints, and patents, and unlock new insights that can propel your discoveries forward.
Expand your knowledge of Selective Estrogen Receptor Modulators (SERMs) and explore the versatility of these compounds through the lens of PubCompare.ai's innovative solutions.
Embark on a journey of enhanced research efficiency and groundbreaking discoveries in the realm of SERM-based therapeutics.